Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt 2.11
NKTR's Cash to Debt is ranked higher than
66% of the 925 Companies
in the Global Biotechnology industry.

( Industry Median: 16.07 vs. NKTR: 2.11 )
NKTR' s 10-Year Cash to Debt Range
Min: 0.72   Max: 389.59
Current: 2.11

0.72
389.59
Equity to Asset -0.07
NKTR's Equity to Asset is ranked higher than
51% of the 771 Companies
in the Global Biotechnology industry.

( Industry Median: 0.65 vs. NKTR: -0.07 )
NKTR' s 10-Year Equity to Asset Range
Min: -0.21   Max: 0.92
Current: -0.07

-0.21
0.92
F-Score: 6
Z-Score: -3.44
M-Score: -2.79
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating margin (%) -72.49
NKTR's Operating margin (%) is ranked higher than
72% of the 832 Companies
in the Global Biotechnology industry.

( Industry Median: -65.07 vs. NKTR: -72.49 )
NKTR' s 10-Year Operating margin (%) Range
Min: -335.29   Max: -13.24
Current: -72.49

-335.29
-13.24
Net-margin (%) -101.92
NKTR's Net-margin (%) is ranked higher than
69% of the 832 Companies
in the Global Biotechnology industry.

( Industry Median: -69.57 vs. NKTR: -101.92 )
NKTR' s 10-Year Net-margin (%) Range
Min: -322.72   Max: -12
Current: -101.92

-322.72
-12
ROE (%) -140.39
NKTR's ROE (%) is ranked higher than
55% of the 877 Companies
in the Global Biotechnology industry.

( Industry Median: -28.59 vs. NKTR: -140.39 )
NKTR' s 10-Year ROE (%) Range
Min: -140.39   Max: -14.84
Current: -140.39

-140.39
-14.84
ROA (%) -32.58
NKTR's ROA (%) is ranked higher than
68% of the 925 Companies
in the Global Biotechnology industry.

( Industry Median: -21.69 vs. NKTR: -32.58 )
NKTR' s 10-Year ROA (%) Range
Min: -38.56   Max: -4.39
Current: -32.58

-38.56
-4.39
ROC (Joel Greenblatt) (%) -147.90
NKTR's ROC (Joel Greenblatt) (%) is ranked higher than
74% of the 914 Companies
in the Global Biotechnology industry.

( Industry Median: -217.20 vs. NKTR: -147.90 )
NKTR' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -203.29   Max: -27.52
Current: -147.9

-203.29
-27.52
Revenue Growth (%) -3.10
NKTR's Revenue Growth (%) is ranked higher than
73% of the 646 Companies
in the Global Biotechnology industry.

( Industry Median: -0.90 vs. NKTR: -3.10 )
NKTR' s 10-Year Revenue Growth (%) Range
Min: -31.4   Max: 61.5
Current: -3.1

-31.4
61.5
EBITDA Growth (%) 9.30
NKTR's EBITDA Growth (%) is ranked higher than
86% of the 621 Companies
in the Global Biotechnology industry.

( Industry Median: -8.10 vs. NKTR: 9.30 )
NKTR' s 10-Year EBITDA Growth (%) Range
Min: -48.7   Max: 90.5
Current: 9.3

-48.7
90.5
EPS Growth (%) 10.60
NKTR's EPS Growth (%) is ranked higher than
86% of the 649 Companies
in the Global Biotechnology industry.

( Industry Median: -10.10 vs. NKTR: 10.60 )
NKTR' s 10-Year EPS Growth (%) Range
Min: -44.4   Max: 101
Current: 10.6

-44.4
101
» NKTR's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2013

NKTR Guru Trades in Q3 2013

PRIMECAP Management 9,953,856 sh (+31.41%)
Steven Cohen Sold Out
» More
Q4 2013

NKTR Guru Trades in Q4 2013

Steven Cohen 58,722 sh (New)
PRIMECAP Management 12,498,386 sh (+25.56%)
» More
Q1 2014

NKTR Guru Trades in Q1 2014

PRIMECAP Management 15,534,086 sh (+24.29%)
Steven Cohen Sold Out
» More
Q2 2014

NKTR Guru Trades in Q2 2014

PRIMECAP Management 15,804,286 sh (+1.74%)
» More
» Details

Insider Trades

Latest Guru Trades with NKTR

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
PRIMECAP Management 2014-03-31 Add 24.29%0.04%$11.35 - $14.96 $ 11.99-9%15534086
PRIMECAP Management 2013-12-31 Add 25.56%0.03%$8.96 - $12.56 $ 11.9912%12498386
PRIMECAP Management 2013-09-30 Add 31.41%0.03%$10.541 - $13.96 $ 11.99-3%9953856
PRIMECAP Management 2012-12-31 Reduce -29.07%0.05%$5.99 - $10.83 $ 11.9948%6469856
Jean-Marie Eveillard 2011-12-31 Sold Out 0.003%$4.22 - $5.62 $ 11.99145%0
Jean-Marie Eveillard 2011-09-30 New Buy$4.98 - $7.65 $ 11.99101%125000
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/S 10.40
NKTR's P/S is ranked higher than
79% of the 984 Companies
in the Global Biotechnology industry.

( Industry Median: 20.06 vs. NKTR: 10.40 )
NKTR' s 10-Year P/S Range
Min: 1.76   Max: 16.68
Current: 10.4

1.76
16.68
EV-to-EBIT -13.10
NKTR's EV-to-EBIT is ranked higher than
79% of the 984 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. NKTR: -13.10 )
NKTR' s 10-Year EV-to-EBIT Range
Min: 8.5   Max: 685.7
Current: -13.1

8.5
685.7
Current Ratio 3.54
NKTR's Current Ratio is ranked higher than
72% of the 921 Companies
in the Global Biotechnology industry.

( Industry Median: 4.02 vs. NKTR: 3.54 )
NKTR' s 10-Year Current Ratio Range
Min: 1   Max: 16.32
Current: 3.54

1
16.32
Quick Ratio 3.37
NKTR's Quick Ratio is ranked higher than
72% of the 921 Companies
in the Global Biotechnology industry.

( Industry Median: 3.81 vs. NKTR: 3.37 )
NKTR' s 10-Year Quick Ratio Range
Min: 0.96   Max: 16.32
Current: 3.37

0.96
16.32

Valuation & Return

vs
industry
vs
history
Price/Median PS Value 1.06
NKTR's Price/Median PS Value is ranked higher than
82% of the 984 Companies
in the Global Biotechnology industry.

( Industry Median: 1.94 vs. NKTR: 1.06 )
NKTR' s 10-Year Price/Median PS Value Range
Min: 0.2   Max: 4.48
Current: 1.06

0.2
4.48
Earnings Yield (Greenblatt) 772.10
NKTR's Earnings Yield (Greenblatt) is ranked higher than
97% of the 475 Companies
in the Global Biotechnology industry.

( Industry Median: 5.00 vs. NKTR: 772.10 )
NKTR' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.1   Max: 1046.5
Current: 772.1

0.1
1046.5
Forward Rate of Return (Yacktman) -8.79
NKTR's Forward Rate of Return (Yacktman) is ranked higher than
77% of the 768 Companies
in the Global Biotechnology industry.

( Industry Median: -10.16 vs. NKTR: -8.79 )
NKTR' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -38   Max: -26.1
Current: -8.79

-38
-26.1

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:ITH.Germany
Nektar Therapeutics, Inc, was incorporated in California in 1990 and reincorporated in Delaware in 1998. The Company is a clinical-stage biopharmaceutical company developing a pipeline of drug candidates that utilize its PEGylation and polymer conjugate technology platforms, which are designed to improve the benefits of drugs for patients. Its current proprietary pipeline is comprised of drug candidates across a number of therapeutic areas including oncology, pain, anti-infectives, anti-viral and immunology. Its research and development activities involve small molecule drugs, peptides and other potential biologic drug candidates. The Company creates its innovative drug candidates by using its proprietary advanced polymer conjugate technologies and expertise to modify the chemical structure of drugs to create new molecular entities. The Company's drug candidates are designed to improve the pharmacokinetics, pharmacodynamics, half-life, bioavailability, metabolism or distribution of drugs and improve the overall benefits and use of a drug for the patient. It's most advanced proprietary drug candidate, NKTR-118, is an oral peripherally-acting opioid antagonist, currently in Phase 3 clinical studies for the treatment of opioid-induced constipation (OIC) in patients with non-cancer pain and cancer pain. OIC is a common side effect of prescription opioids when used for chronic pain management. In September 2009, the Company entered into a global license agreement with AstraZeneca AB for the global development and commercialization of NKTR-118 and NKTR-119. NKTR-119 is an early stage research and development program that is designed to combine various opioids with NKTR-118. AstraZeneca is responsible for all clinical, regulatory and commercialization costs for NKTR-118 and NKTR-119. The Company has several proprietary pre-clinical and clinical drug candidates that are in the pain therapeutic area. NKTR-181 is an orally-available mu-opioid analgesic molecule with a long-acting profile to treat chronic pain that has been designed with the objective of addressing serious CNS-related side effects associated with standard opioid therapies. The Company frequently competes with pharmaceutical companies and other institutions. As a manufacturer of PEG reagents for the U.S. market, the Company is subject to inspections by the FDA for compliance with cGMP and other U.S. regulatory requirements, including U.S. federal, state and local regulations regarding environmental protection and hazardous and controlled substance controls, among others. Environmental laws and regulations are complex, change frequently and have tended to become more stringent over time.
» More Articles for NKTR

Headlines

Articles On GuruFocus.com
Weekly Guru Bargains Highlights: AKAM, NKTR, LOGI, FFIV, LCC Apr 16 2011 
Weekly Guru Bargains Highlights: AMSC, LOGI, NKTR, DAL, AIG Apr 09 2011 
Four Guru Stocks near New Lows: FBN, HOME, NKTR, PETS Feb 07 2011 
MannKind: Deja Vu for the FDA and Afrezza Dec 29 2010 
Nektar Therapeutics Reports Operating Results (10-Q) Nov 04 2010 
Nektar Therapeutics Reports Operating Results (10-Q) Jul 29 2010 
Nektar Therapeutics Reports Operating Results (10-Q) May 06 2010 
cooldecency99 note on NKTR May 01 2010 
Small-Cap Biotech Stocks: Why This Sector Is Set for a Huge Year Jan 06 2010 
Nektar Therapeutics Reports Operating Results (10-Q) Nov 05 2009 


More From Other Websites
Nektar/AstraZeneca's Moventig a Step Closer to EU Approval Sep 29 2014
Nektar Therapeutics Announces MOVENTIG® (naloxegol) Receives Positive CHMP Opinion In EU For... Sep 26 2014
Nektar Presents Positive Preclinical Data on Oral, Peripherally-Acting Kappa Agonist Molecules at... Sep 19 2014
Nektar says FDA clears constipation drug Movantik Sep 16 2014
Nektar says FDA clears constipation drug Movantik Sep 16 2014
BUZZ-Nektar Therapeutics: FDA approves constipation drug Sep 16 2014
FDA Approves MOVANTIK™ (naloxegol) Tablets For The Treatment Of Opioid-Induced Constipation In... Sep 16 2014
FDA approves AstraZeneca, Nektar constipation drug Sep 16 2014
FDA approves AstraZeneca, Nektar constipation drug Sep 16 2014
Baxter Announces Positive Top-Line Results from Its Phase 3 Study of BAX 855, Extended Half-Life... Aug 21 2014
NEKTAR THERAPEUTICS Financials Aug 08 2014
Nektar's Loss Narrows in Q2, Beats Revenues, Retains View Aug 01 2014
NEKTAR THERAPEUTICS Files SEC form 10-Q, Quarterly Report Aug 01 2014
NEKTAR THERAPEUTICS Files SEC form 8-K, Results of Operations and Financial Condition, Financial... Jul 31 2014
Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 Jul 31 2014
Q2 2014 NEKTAR THERAPEUTICS Earnings Release - After Market Close Jul 31 2014
Nektar to Announce Financial Results for the Second Quarter 2014 on Thursday, July 31, 2014, After... Jul 22 2014
NEKTAR THERAPEUTICS Files SEC form 8-K, Change in Directors or Principal Officers, Submission of... Jun 27 2014
Cara Therapeutics appoints Medve Chief Medical Officer Jun 24 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK